Infectious Disease and Drug Discovery Meeting
Bentley University
Waltham, MA
June 20, 2008
Schedule:
8:00 - 9:00 am | Check-in and breakfast |
9:00 - 9:05 am | Opening Remarks |
9:05 - 10:00 am | Antibacterial Drug Discovery in the 21st Century: Is There Any Hope? Steve Projan, Wyeth Research, Cambridge, MA |
10:00 - 10:30 am | Riboswitches: RNA receptors as antibacterial drug targets Ken Blount, Biorelix Pharmaceutical, Inc, New Haven, CT |
10:30 - 11:00 am | Break |
11:00 - 11:30 am | Structure Guided Target Evaluation for Antibacterial Drug Discovery Sushmita Lahiri, AstraZeneca Pharmaceuticals, Waltham, MA |
11:30 - 12:00 pm | Structure-based Drug Design Targeting Infectious Disease Zoltan Kanyo, Rib-X Pharmaceuticals, New Haven, CT |
12:00 - 1:00 pm | Lunch |
1:00 - 2:00 pm | Structural Biology and an Effective HIV-1 Vaccine Peter Kwong, Vaccine Research Center, NIH, Bethesda, MD |
2:00 - 3:00 pm | Reducing Risk in Drug Discovery, Preclinical Development of the Hepatitis C Virus Protease Inhibitor Telaprevir (VX-950) Ann Kwong, Vertex Pharmaceuticals, Cambridge, MA |
3:00 - 3:30 pm | Break |
3:30 - 4:00 pm | Biophysical Approaches to Target-Based Discovery of Novel Antibacterials Gunther Kern, AstraZeneca Pharmaceuticals, Waltham, MA |
4:00 - 5:00 pm | Mining the Magic Mountain for Novel Inhibitors of Menaquinone and Fatty Acid Biosynthesis in Mycobacterium Tuberculosis: Slow Onset Inhibition and In Vivo Activity Peter Tonge, Institute for Chemical Biology and Drug Discovery, SUNY Stony Brook, NY |
5:00 - 7:00 pm | Mixer |